Clinical trial
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
NCT02299570 · Rebiotix Inc., Industry · Completed
Key facts
| NCT number | NCT02299570 |
|---|---|
| Title | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection |
| Official title | A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection |
| Acronym | PUNCHCD2 |
| Lead sponsor | Rebiotix Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Enterocolitis Clostridium Difficile Recurrent |
| Intervention type | Biological, Other |
| Interventions | RBX2660 (microbiota suspension), Placebo |
| Enrollment | 150 |
| Start date | Dec 1, 2014 |
| Primary completion | Jan 1, 2016 |
| Completion | Jan 1, 2018 |
| First posted | Nov 24, 2014 |
| Last update posted | Jan 15, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: